Malignant Hepatobiliary Neoplasm
specificA malignant neoplasm that affects the liver parenchyma, bile ducts, and gallbladder. Representative examples include hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.
39
Centers
42
Active Trials
—
Cancer Funding
Top Centers for Malignant Hepatobiliary Neoplasm(39)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive High-Volume Research Center | 71.5 |
| 2 | University of Illinois Cancer CenterChicago, IL High-Volume Research Center | 71.5 |
| 3 | Cancer Center at IllinoisUrbana, IL High-Volume Research Center | 71.5 |
| 4 | University of Texas Medical Branch Cancer CenterGalveston, TX High-Volume Research Center | 71.5 |
| 5 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 49.6 |
| 6 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 49.6 |
| 7 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 49.6 |
| 8 | NCI Comprehensive Active Research Program | 49.6 |
| 9 | NCI Comprehensive Active Research Program | 49.6 |
| 10 | NCI Comprehensive Active Research Program | 49.6 |
| 11 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 49.6 |
| 12 | NCI Comprehensive Active Research Program | 49.6 |
| 13 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 49.6 |
| 14 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive Active Research Program | 49.6 |
| 15 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 49.6 |
| 16 | UF Health Cancer InstituteGainesville, FL NCI Clinical Active Research Program | 49.6 |
| 17 | UC Davis Comprehensive Cancer CenterSacramento, CA NCI Comprehensive Active Research Program | 49.6 |
| 18 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 49.6 |
| 19 | NCI Clinical Active Research Program | 49.6 |
| 20 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 49.6 |
| 21 | NCI Comprehensive Active Research Program | 49.6 |
| 22 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 49.6 |
| 23 | Georgetown Lombardi Comprehensive Cancer CenterWashington, DC NCI Comprehensive Active Research Program | 49.6 |
| 24 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 49.6 |
| 25 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 49.6 |
| 26 | University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive Active Research Program | 49.6 |
| 27 | Boston University Cancer CenterBoston, MA Active Research Program | 49.6 |
| 28 | Active Research Program | 49.6 |
| 29 | Stony Brook Cancer CenterStony Brook, NY Active Research Program | 49.6 |
| 30 | Penn State Cancer InstituteHershey, PA Active Research Program | 49.6 |
| 31 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 49.6 |
| 32 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program | 49.6 |
| 33 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 49.6 |
| 34 | Georgia Cancer Center, Augusta UniversityAugusta, GA Active Research Program | 49.6 |
| 35 | Ellis Fischel Cancer Center, MU Health CareColumbia, MO Active Research Program | 49.6 |
| 36 | Loma Linda University Cancer CenterLoma Linda, CA Active Research Program | 49.6 |
| 37 | Active Research Program | 49.6 |
| 38 | Louisiana Cancer Research CenterNew Orleans, LA Active Research Program | 49.6 |
| 39 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive | 29.4 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →